Indegene Ltd Valuation Shifts to Fair Amidst Market Pressure

Valuation Metrics and Recent Changes

As of 16 Feb 2026, Indegene’s P/E ratio stands at 25.99, a figure that has contributed to the company’s valuation grade being downgraded from attractive to fair. This marks a notable shift from previous assessments where the stock was considered undervalued relative to its earnings potential. The price-to-book value ratio has also risen to 3.98, indicating that the market is pricing the company at nearly four times its book value, a level that tempers the earlier enthusiasm among investors.

Other valuation multiples provide additional context: the enterprise value to EBIT (EV/EBIT) ratio is 20.63, while the EV to EBITDA ratio is 17.02. These multiples, though elevated, remain below some of the more expensive peers in the sector, signalling that while Indegene’s valuation has firmed, it is not yet stretched to extremes.

Comparative Analysis with Peers

When benchmarked against its healthcare services peers, Indegene’s valuation appears more reasonable. For instance, Tata Elxsi and Tata Technologies are classified as very expensive, with P/E ratios of 46.08 and 41.92 respectively, and EV/EBITDA multiples exceeding 28. In contrast, Indegene’s P/E and EV/EBITDA ratios are significantly lower, suggesting a relative value proposition despite the recent re-rating.

However, some peers such as Zensar Technologies and KPIT Technologies also hold fair valuation grades, with P/E ratios of 17.6 and 30.95 respectively. This places Indegene in a middle ground within the sector, neither the cheapest nor the most expensive, reflecting a balanced market view on its growth prospects and risk profile.

Financial Performance and Quality Metrics

Indegene’s return on capital employed (ROCE) is a robust 28.47%, underscoring efficient utilisation of capital and operational strength. Return on equity (ROE) at 15.56% further supports the company’s ability to generate shareholder value. These quality metrics justify a valuation premium to some extent, though the market appears to be pricing in a more cautious outlook given the recent downgrade in the Mojo Grade from Sell to Hold on 12 Jan 2026.

The company’s dividend yield remains modest at 0.42%, which is typical for growth-oriented healthcare service providers reinvesting earnings into expansion and innovation.

Stock Price and Market Performance

Indegene’s current share price is ₹474.50, up slightly from the previous close of ₹470.05. The stock has traded within a 52-week range of ₹455.80 to ₹632.10, indicating some volatility but also a significant correction from its highs. Intraday trading on 16 Feb 2026 saw a high of ₹486.80 and a low of ₹461.00, reflecting investor indecision amid valuation concerns.

Performance relative to the broader market has been challenging. Year-to-date, Indegene has declined by 8.85%, compared to a 3.04% gain in the Sensex. Over the past year, the stock has fallen 21.13%, while the Sensex has appreciated by 8.52%. This underperformance highlights the market’s cautious stance on the company’s near-term growth prospects despite its solid fundamentals.

Mojo Score and Grade Implications

Indegene’s Mojo Score currently stands at 52.0, placing it in the Hold category. This is a marked improvement from its previous Sell rating, reflecting a more balanced risk-reward profile. The upgrade on 12 Jan 2026 signals that while the stock is no longer considered a strong sell, investors should remain cautious given the fair valuation and recent price underperformance.

The Market Cap Grade of 3 further indicates a mid-tier market capitalisation status, which may limit liquidity compared to larger healthcare services companies but also offers potential for growth if the company can capitalise on sector tailwinds.

Sector and Market Context

The healthcare services sector continues to attract investor interest due to demographic trends and increasing healthcare expenditure. However, valuations across the sector have generally expanded, with several peers trading at very expensive multiples. Indegene’s shift to a fair valuation grade suggests that the market is recalibrating expectations, possibly factoring in competitive pressures and macroeconomic uncertainties.

Investors should weigh Indegene’s strong operational metrics against its relative price performance and valuation re-rating. While the company’s fundamentals remain solid, the stock’s recent underperformance relative to the Sensex and peers indicates that upside may be limited in the near term without a catalyst to improve growth visibility or margin expansion.

Investor Takeaway

Indegene Ltd’s transition from an attractive to a fair valuation grade reflects a maturing market view on the company’s prospects. While the stock remains competitively valued relative to some very expensive peers, its recent price underperformance and moderate dividend yield suggest that investors should adopt a cautious stance.

Quality metrics such as ROCE and ROE remain strong, supporting the company’s operational efficiency and shareholder value creation. However, the elevated P/E and P/BV ratios imply that much of the growth potential is already priced in, limiting the margin of safety for new investors.

Given the current market environment and sector valuation trends, Indegene may be best suited for investors with a medium to long-term horizon who can tolerate near-term volatility in exchange for exposure to a fundamentally sound healthcare services business.

Summary of Key Valuation and Performance Metrics

• P/E Ratio: 25.99 (Fair valuation grade)
• Price to Book Value: 3.98
• EV/EBITDA: 17.02
• ROCE: 28.47%
• ROE: 15.56%
• Dividend Yield: 0.42%
• Mojo Score: 52.0 (Hold)
• Market Cap Grade: 3
• 1Y Stock Return: -21.13% vs Sensex +8.52%

Investors should continue to monitor valuation trends and sector developments closely, as any improvement in earnings visibility or margin expansion could prompt a re-rating. Conversely, sustained market weakness or sector headwinds may further pressure the stock’s price.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →